Table 1.
Patients’ demographic, clinical and pathological characteristics according to secreted YB1 (sYB1) status.
| Variable list | Full cohort (n=44) | Positive YB-1 (n=22) | Negative YB-1 (n=22) | p-value |
|---|---|---|---|---|
| Age (years) | ||||
| Median | 54.3 | 48.4 | 55.2 | 0.639 |
| IQR | 44.0 – 62.3 | 40.9 – 62.1 | 44.5–62.4 | |
| Age (years), n (%) | ||||
| < 35 | 1 (2.3) | 1 (4.6) | 0 (0) | 0.245 |
| 35–49 | 19 (43.2) | 11 (50.0) | 8 (36.4) | |
| 50–69 | 18 (40.9) | 6 (27.3) | 12 (54.6) | |
| ≥ 70 | 6 (13.6) | 4 (18.2) | 2 (9.1) | |
| Histology, n (%) | ||||
| Ductal carcinomas | 34 (82.9) | 17 (85.0) | 17 (81.0) | 1.000 |
| Lobular carcinomas | 3 (7.3) | 1 (5.0) | 2 (9.5) | |
| Other | 4 (9.8) | 2 (10.0) | 2 (9.5) | |
| Missing | 3 (6.8) | 2 (9.1) | 1 (4.6) | |
| Hormone receptor status, n (%) | ||||
| ER or PR positive | 32 (76.2) | 18 (85.7) | 14 (66.7) | 0.277 |
| ER and PR negative | 10 (23.8) | 3 (14.3) | 7 (33.3) | |
| Missing | 2 (4.6) | 1 (4.6) | 1 (4.6) | |
| HER2 receptor status, n (%) | ||||
| Positive | 7 (19.4) | 4 (22.2) | 3 (16.7) | 1.000 |
| Negative | 29 (80.6) | 14 (77.8) | 15 (83.3) | |
| Missing | 8 (18.2) | 4 (18.2) | 4 (18.2) | |
| Metastatic at diagnosis, n (%) | ||||
| Yes | 8 (19.5) | 4 (18.2) | 4 (21.1) | 1.000 |
| No | 33 (80.5) | 18 (81.8) | 15 (79.0) | |
| Missing | 3 (6.8) | 0 (0) | 3 (13.6) | |
| Age at diagnosis of bone involvement | ||||
| Median | 61.3 | 59.1 | 61.3 | 0.706 |
| P25 – P75 | 49.6–68.1 | 46.8–75.9 | 52.8–67.0 | |
| Missing, n (%) | 2 (4.5) | 0 (0) | 2 (9.1) | |
| Radiographic pattern of bone lesions, n (%) | ||||
| Lytic | 24 (60.0) | 15 (71.4) | 9 (47.4) | 0.064 |
| Blastic | 6 (15.0) | 4 (19.1) | 2 (10.5) | |
| Mixed | 10 (25.0) | 2 (9.5) | 8 (42.1) | |
| Missing | 4 (9.1) | 1 (4.6) | 3 (13.6) | |
| Metastatic disease outside bone, n (%) | ||||
| Yes | 28 (65.1) | 18 (81.8) | 10 (47.6) | 0.019 |
| No | 15 (34.9) | 4 (18.2) | 11 (52.4) | |
| Missing, n (%) | 1 (2.3) | 0 (0) | 1 (4.6) | |
| Time to disease recurrence in patients stage I-III | ||||
| Median | 66.0 | 61.6 | 71.3 | 0.715 |
| P25-P75 | 38.5–126.1 | 38.5 – 126.1 | 34.7–130.8 | |
| Time to bone-disease recurrence in patients stage I-III | ||||
| Median | 75.9 | 73.1 | 76.2 | 1.000 |
| P25-P75 | 45.4–130.8 | 39.9–137.9 | 59.8–130.8 | |
| Overall survival follow-up from date of bone recurrence, months | ||||
| Median | 34.0 | 29.4 | 57.9 | 0.060 |
| P25-P75 | 21.1–74.5 | 17.6–50.3 | 21.1–107.6 | |